Pharmaceutical AI for drug discovery, pharmacovigilance, clinical trials, and regulatory submissions. Signal detection. Trial outcome prediction. FDA, EMA & 15+ jurisdictions.
NOVA detects pharmacovigilance signals before they become events. Predicts clinical trial outcomes. Models competitive pipeline intelligence. Supports FDA, EMA, CDSCO and 12+ other regulatory submissions.
Composite signal score from case volume, disproportionality, clinical plausibility, temporal association.
Estimates endpoint achievement probability from interim data. Enables adaptive design decisions.
FDA, EMA, CDSCO, PMDA & 11+ jurisdictions. Automated document generation and compliance checks.
Non-classified signals flow from NOVA to sibling models — enabling cross-domain intelligence that no single-domain AI can produce.
Non-classified pharmacovigilance signals · drug interaction data · trial outcome patterns · regulatory timelines
Pharmacovigilance signal detection at scale. Clinical trial outcome prediction from interim data. Regulatory submission support across 15+ jurisdictions.
Composite signal score from case volume, disproportionality, clinical plausibility, temporal association — all automated.
NOVA models project endpoint probability from interim analyses — enabling adaptive trial design decisions.
FDA, EMA, PMDA, CDSCO, MHRA, Health Canada, TGA, ANVISA — automated document generation tailored per regulator.
NOVA's drug safety signals flow to SAGE in real time — clinicians see the latest pharmacovigilance intelligence within their care pathway tools.
24/7 signal detection · automated PSUR / DSUR · regulatory submission prep.
Interim analysis · endpoint prediction · adaptive design recommendations.
Multi-jurisdiction submissions · compliance monitoring · change impact.
Publication support · KOL intelligence · competitive landscape tracking.
Request a demo tailored to your specific deployment — we'll walk you through the model, KCL integration, and onboarding timeline.